Core Viewpoint - Fosen Pharmaceutical (01652) experienced a significant stock price surge, rising over 410% at one point and currently up 350%, trading at HKD 1.53 with a transaction volume of HKD 13.89 million [1] Group 1: Company Developments - Fosen Pharmaceutical announced that its research and development product, "Metformin and Empagliflozin Tablets (I)", has received approval from the National Medical Products Administration of China [1] - The approved indication for the product is for the treatment of adult patients with type 2 diabetes who are currently receiving Empagliflozin and Metformin hydrochloride, aimed at improving blood glucose control in these patients [1] - The board believes that Metformin and Empagliflozin Tablets (I) is an important addition to the company's product pipeline in the diabetes treatment sector, providing more treatment options for diabetes patients [1]
港股异动 | 福森药业(01652)一度飙升逾410% “二甲双胍恩格列净片(I)”获批上市